Recent clinical trials for malignant glioma have drawn attention to the potential therapeutic efficacy of herpes simplex virusthymidine kinase (HSV-tk) suicide gene therapy. Nevertheless, because of the nature of these tumors, it is believed that no single treatment alone is able to combat this fatal disease. Combination therapies may provide a solution to further improve therapies against malignant gliomas. We have recently demonstrated that 15-lipoxygenase-1 (15-LO-1) is able to inhibit tumor angiogenesis as well as enhance apoptosis in tumors. As a result, we studied the potential additive/synergistic effects of 15-LO-1 gene therapy when combined with HSV-tk gene therapy for the treatment of malignant gliomas. For that, BT4C malignant glioma cells were implanted into BDIX male rats. Fourteen days after tumor cell implantation, animals were transduced using adenoviral vectors either with HSV-tk alone or in combination with 15-LO-1. The results show that the combination gene therapy neither improved inhibition of tumor growth nor did it show any benefit on survival. Instead, a profound effect on the migratory properties of the tumor cells was found, resulting in decreased survival. Similar to conventional therapies, the combination of two therapeutic genes may result in unexpected side effects, not seen when given alone.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most malignant as well as most frequent brain tumor in adults and in general one of the most fatal and refractory cancers in humans. As the name already implies, GBMs have a wide spectrum of histological morphologies ranging from small-cell type to very pleomorphic giant cell forms with poor differentiation and gliosarcomas. 1, 2 It is highly resistant to all conventionally applied therapies and despite advances in surgery, radiation and chemotherapy, only marginal clinical improvements have been achieved. 3 Pre-clinical and clinical trials of herpes simplex virus thymidine kinase (HSV-tk) suicide gene therapy have recently drawn attention as a potential treatment modality for malignant gliomas. [4] [5] [6] However, despite promising results, there is still a demand to further improve the efficacy of HSV-tk gene therapy. A potential approach is the combination of HSV-tk suicide gene therapy with another therapeutic modality, for example, anti-angiogenic therapy. GBMs are characterized by strong angiogenesis and a high degree of vascular proliferation and endothelial cell hyperplasia. 7 The recent approval by the US Food and Drug Administration of bevacizumab (Avastin), a monoclonal antibody against the growth factor vascular endothelial growth factor-A, for the treatment of GBM further supports the rationale of anti-angiogenic therapy for the treatment of malignant gliomas. 8 15-Lipoxygenase-1 (15-LO-1) is a multifunctional enzyme able to produce a vast number of metabolites with diverse bioactivities. 9 Its expression has been demonstrated to be significantly decreased in several cancers, including breast, bladder, colon, skin and lung carcinomas. 10 A recent report by Viita et al. 11, 12 demonstrated that 15-LO-1 is able to prevent vascular endothelial growth factor-A-induced neovascularisation in rabbit eyes and skeletal muscle. Consequently, Viita et al. 13 evaluated the therapeutic efficacy of 15-LO-1 as a treatment for malignant gliomas. Therein, animals treated with adenoviral 15-LO-1 gene therapy survived significantly longer than control animals. Furthermore, in that study Viita et al. 13 showed that 15-LO-1 may have additionally a prominent role in tumor cell apoptosis, which was attributed to the induction of lipid peroxidation followed by stimulation of caspase-3-mediated apoptosis. Consequently, this potential dual mechanism of 15-LO-1 may be a promising therapeutic molecule for combination gene therapy in GBM to further improve the therapeutic outcome of HSV-tk gene therapy. Therefore, we hypothesized that combination of 15-LO-1 with HSV-tk suicide gene therapy could further improve survival of malignant gliomabearing rats compared with 15-LO-1 or HSV-tk monotherapy.
MATERIALS AND METHODS

Therapeutic studies
In total, 31 male BDIX rats (Charles River Laboratories, France) were injected with 10 4 BT4C cells/animal resuspended in 10 ml of Dulbecco's modified Eagle's medium to the depth of 2.5 mm into the right corpus callosum as described previously.
14 The rats were divided into three cohorts: (1) the study group, which received 15-LO-1 and HSV-tk combination gene therapy accompanied by ganciclovir treatment (n ¼ 13), and two control groups, of which one received HSV-tk gene therapy accompanied with ganciclovir treatment (n ¼ 9) and the other group 15-LO-1 (n ¼ 9) as monotherapies.
Gene transfer was performed 15 or 16 days after tumor cell implantation using adenoviral vectors encoding for HSV-tk (AdHSV-tk) or 15-LO-1 (Ad15-LO-1). Control animals received a total of either 15 ml of AdHSV-tk (titer ¼ ), whereas the combination group received a total of 27.5 ml of viral vectors (15 ml of AdHSV-tk plus 12.5 ml of 15-LO-1). Gene transfer was performed into the tumors on 2 consecutive days. In the combination group, AdHSV-tk was injected to the depth of 1.0, 1.5, 2.0 and 2.5 mm from the bregma level, whereas 15-LO-1 was applied in two injections to the sides at 2 mm depth made by flexing the C-arm of the microinjection unit ( Figure 1a ). On the following day, the Ad15-LO-1 was injected to the depth of 1.5, 2.0 and 2.5 mm from the bregma level, whereas the AdHSV-tk was applied in two injections 2 mm depth at an angle ( Figure 1b ). In the HSV-tk monotherapy group, gene transfer was performed to the depth of 1.0, 1.5, 2.0 mm and 2.5 mm from the bregma level and two injections to the sides on 2 consecutive days (Figure 1a) , and in the 15-LO-1 monotherapy group, gene transfer was performed to the depth of 1.5, 2.0 and 2.5 mm from the bregma level, with two injections to the sides (Figure 1b) . The recombinant Adh15-LO-1 adenovirus and control AdHSV-tk virus were produced in 293 cells as described previously. 12, 15 Gancyclovir hydrochloride (Roche, Espoo, Finland) treatment was started 5 days after the final gene transfer, at a total dose of 50 mg kg À 1 per day per rat, given in two divided doses of 25 mg kg À 1 each 12 h apart. The treatment was continued for 14 days. Animals were followedup and killed with CO 2 overdose upon humane endpoints. Survival analysis was done using Kaplan-Meier survival plots, and the survival curves were compared using the Mantel-Cox log-rank test. Po0.05 was considered statistically significant.
Immunohistochemistry
Brains were removed from the animals and fixed overnight with 4% paraformaldehyde solution and further paraffin embedded. Tissue sections were stained with standard haematoxylin and eosin staining or CD34-periodic acid-Schiff dual staining as described previously. 16 CD34 expression was detected from paraffin sections using goat polyclonal antibody (R&D, Minneapolis, MN, USA; 1:500 dilution). To identify matrixassociated vascular channels, after CD34 staining, tissues were stained with periodic acid-Schiff (Sigma-Aldrich, Gillingham, UK) and counterstained with Mayer's haematoxylin.
RESULTS
Combination of HSV-tk and 15-LO-1 gene therapy did not result in improvement of survival
The results demonstrate that the combination of HSV-tk and 15-LO-1 gene therapy did not result in further improvement of survival in malignant glioma-bearing rats (Figure 2 and Tables 1  and 2 ). Instead, the median survival dropped in the combination group compared with HSV-tk or 15-LO-1 monotherapy (Table 2) . Even though statistical significance was not reached between the groups, there was a clear trend in worsened prognosis in the study group compared with the control groups.
HSV-tk and 15-LO-1 combination gene therapy-induced invasiveness of BT4C malignant gliomas An aspect that further supported our finding of worsened prognosis with HSV-tk and 15-LO-1 combination gene therapy ), whereas the combination group received a total of 27.5 ml of viral vectors (15 ml of AdHSV-tk plus 12.5 ml of 15-LO-1). The study group were injected with AdHSV-tk to the depth of 1.0, 1.5, 2.0 and 2.5 mm from the bregma level and 15-LO-1, which was injected to the sides at 2 mm depth made by flexing the C-arm of the microinjection unit (a). On the following day, the Ad15-LO-1 was injected to the depth of 1.5, 2.0 and 2.5 mm from the bregma level, whereas the AdHSV-tk was applied in two injections 2 mm depth at an angle (b). In the HSV-tk monotherapy group, gene transfer was performed to the depth of 1.0, 1.5, 2.0 and 2.5 mm from the bregma level and two injections to the sides on 2 consecutive days (a) and in the 15-LO-1 monotherapy group gene transfer was performed to the depth of 1.5, 2.0 and 2.5 mm from the bregma level, with two injections to the sides (b). A, anterior; P, posterior. animals (23%) toward infiltration into healthy tissue and profound migration (Figure 3a) , a finding we have not observed before in any of our previous studies when 15-LO-1 or HSV-tk were given as monotherapy. 4, 13 In these animals, single cell infiltration as well as (Figure 3b ), whole clusters of migrating cells into normal brain parenchyma were particularly seen in vastly vascularized areas (Figure 3c) . A striking increase in the number of small satellite tumors was noted. Those invasive islets were not only surrounding the primary tumor, but also diverged far away from the original inoculation site (Figures 3a and d) . Furthermore, similar to malignant gliomas in humans, 17 we observed a gliomatosis cerebri-like growth pattern in the tumors of animals that were treated with the combination therapy (Figure 3a) . Areas with massive vascular plexus seemed to attract migrating cells, which co-opted pre-existing vessels and traveled along them invading healthy tissue (Figures 3e and f) .
DISCUSSION
Previously, we have shown that both 15-LO-1 and HSV-tk gene monotherapy significantly improves survival of malignant gliomabearing rats. 6, 13 As 15-LO-1 has shown to have anti-angiogenic properties and HSV-tk gene therapy has cytotoxic properties, we hypothesized that the combination of these two therapeutic modalities may further improve the survival of malignant gliomabearing animals. Surprisingly, our results demonstrated that the combination of 15-LO-1 and HSV-tk gene therapy did not improve survival of malignant glioma-bearing rats, but instead, worsened it compared with animals treated with HSV-tk or 15-LO-1 alone ( Table 2 ). The combination of HSV-tk and 15-LO-1 gene therapy seemed to induce the invasiveness of the tumor, demonstrating a gliomatosis cerebri-like growth pattern (Figure 3a) . In addition, vessel co-option was observed within malignant gliomas and their metastasis (Figure 3) . These results demonstrate that anti-angiogenic therapy may elicit tumor adaptation and its progression to an invasive phenotype. 18 Also, studies in pre-clinical animal models have shown accelerated metastatic tumor growth and decreased overall survival after anti-angiogenic therapy. 19, 20 This is thought to be a result of the adaptation to angiogenesis inhibition, leading to increased infiltration and co-option of tumor cells to the host vasculature. 19 Interestingly, the frequency of distant spread and the gliomatosis cerebri-like growth pattern has been shown in 20-30% of patients in response to anti-angiogenic therapy, 17 thereby correlating with the frequency of our study. Currently, we do not know whether the increase in tumor invasiveness was caused by anti-angiogenic properties of 15-LO-1 or yet some other properties of this protein. In this respect, the impact of 15-LO-1 metabolites would be worth studying. Recent insights on cancer cell metabolism (for example, fatty acid synthesis as well as its catabolism) have revealed interesting impact of cancer cell metabolism on its malignancy. 21, 22 As a lipid-peroxidising enzyme 15-LO-1 utilizes linoleic and arachidonic acids as main substrates. 23 15-LO-1 metabolizes linoleic acid to 13-HODE, which has been shown to have anti-angiogenic/antitumorogenic properties. 24 On the contrary, the metabolism of arachidonic acid by 15-LO-1 results in 15-S-hydroxyeicosatetraenoic acid and 12-hydroxyeicosatetraenoic acid. 23 Of these metabolites, 12-hydroxyeicosatetraenoic acid has shown to have pro-tumorigenic/ pro-metastatic properties. 25, 26 It would be interesting to evaluate, whether a change in substrate availability for 15-LO-1 can be detected within the gliomas, resulting in an increase of 12-hydroxy-eicosatetraenoic acid, thereby triggering tumor cell invasion and metastasis. Supportive to this hypothesis is a study by Hakumä ki et al., 27 wherein accumulation of polyunsaturated fatty acids (from which arachidonic acids are derived from) could be detected in the same rat glioma model after HSV-tk gene therapy. Furthermore, in another study it was shown that the level of arachidonic acid may be elevated in cancer as a result of increased lipase activity (for example, monoacylglycerol lipase). 22 In conclusion, it is obvious that 15-LO-1 is a multifunctional enzyme that is able to produce a plethora of bioactive molecules affecting multiple molecular pathways. Depending on the substrate, 15-LO-1 produces a variety of metabolites with different biological effects. Furthermore, the metabolites may be further utilized as substrates to produce a variety of signaling lipids, including prostaglandins and lysophosphatidic acid, which have been demonstrated to influence tumor cell migration and invasion. 22, 28 We have recently demonstrated that 15-LO-1 gene therapy is able to extend survival in the rat malignant glioma model. 13 However, a recent work by Kerjaschki et al. 26 demonstrated that 15-LO-1-mediated invasion of intrametastatic lymphatic vessels and propagated lymph node metastasis of human mammary carcinoma xenografts in mice. These results suggest that whereas single gene therapy may have therapeutic efficacy resulting in a survival advantage, combination therapy may induce a shift in glioblastoma tumor phenotype toward enhanced migration and infiltration of the tumor.
